Insiders · Profile

TZIANABOS ARTHUR

Interim Executive Chair at Stoke Therapeutics · Director at Q32 Bio · President and CSO at Tempest Therapeutics. Filing since 12 Sep 2013. CIK 0001586226

Company
Date
Role
Action
Shares
Amount
Of holding
10 Mar 2026
Interim Executive Chair
Sold on a plan
4,355
$174.21K
12.2%
25 Mar 2024
Director
Sold at will
265
$6.41K
3.2%
9 Jan 2024
Director
Sold on a plan
13,037
$7.45K
9.2%
9 Jan 2023
Director
Sold, plan not stated
10,616
$14.76K
8.9%
5 Jan 2022
President & CEO
Sold, plan not stated
5,354
$20.24K
5.9%
19 Feb 2021
Director
Sold, plan not stated
10,000
$606.65K
100%
23 Nov 2020
Director
Sold, plan not stated
20,000
$920.57K
100%
3 Feb 2020
President & CEO
Sold, plan not stated
12,500
$202.02K
13.9%
2 Jan 2020
President & CEO
Sold, plan not stated
12,500
$256.19K
12.2%
2 Dec 2019
President & CEO
Sold, plan not stated
12,500
$203.18K
10.9%
29 Nov 2019
President & CEO
Sold, plan not stated
12,500
$200.56K
9.8%
1 Oct 2019
President & CEO
Sold, plan not stated
12,500
$217.47K
8.9%
3 Sep 2019
President & CEO
Sold, plan not stated
12,500
$234.32K
8.2%
1 Aug 2019
President & CEO
Sold, plan not stated
12,500
$217.11K
7.6%
1 Jul 2019
President & CEO
Sold, plan not stated
12,500
$237.30K
7.0%
3 Jun 2019
President & CEO
Sold, plan not stated
12,500
$248.26K
6.6%
9 Apr 2015
President and CSO
Bought
225
$6.47K
129%
8 Apr 2015
President and CSO
Bought
175
$4.91K
opened
12 Sep 2013
Chief Scientific Officer
Bought
1,000
$10.32K
opened
19 decisions on file.